MED3000,
does it really help with Improved IIEF-EF and intercourse success in men with erectile dysfunction?
research showsC. Much of the key efficacy evidence comes from an AUA 2024 conference abstract and manufacturer material, with no full peer-reviewed original efficacy report identified. In FM57 (n=250), MED3000 served as the control vehicle for other drug gels. Therefore, MED3000-specific efficacy versus an inactive placebo cannot be estimated. FM71 randomized 96 participants (48/48) in an open-label, tadalafil active-controlled trial. Its Week 24 within-group IIEF-EF MCID endpoint was met for MED3000, but the study was not placebo controlled and did not establish superiority to tadalafil. The vehicle design, open-label active comparator, single-manufacturer program, and reliance on abstracts and manufacturer material support C with 42 points.
ads claimNonprescription medical-device status does not mean placebo-controlled drug efficacy is established. Claims of action within ten minutes and clinical proof must be read alongside FM57's control-gel problem and FM71's open-label active comparator.
Useful facts when choosing a product
- MED3000 is sold as a non-drug, nonprescription medical device massaged onto the glans penis.
- A sensory cooling and rewarming mechanism from volatile ingredients is proposed, but the clinical comparator design did not isolate a gel-specific effect.
- Local burning or discomfort can occur, and headache and nausea were also reported in trials.
- New erectile dysfunction or cardiovascular symptoms warrant clinical evaluation rather than relying only on self-treatment.
Chamgap Semantic Classification Code
Candidate index · review held
P.med3000.topical-skin.iief-ef-and-intercourse-success-with-erectile-dysfunction.improve.MULTIProcedures, devices and tests > MED3000 > Topical skin > IIEF-EF and intercourse success with erectile dysfunction > Improvement claim > Multiple: primary unresolved
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Much of the key efficacy evidence comes from an AUA 2024 conference abstract and manufacturer material, with no full peer-reviewed original efficacy report identified. In FM57 (n=250), MED3000 served as the control vehicle for other drug gels. Therefore, MED3000-specific efficacy versus an inactive placebo cannot be estimated. FM71 randomized 96 participants (48/48) in an open-label, tadalafil active-controlled trial. Its Week 24 within-group IIEF-EF MCID endpoint was met for MED3000, but the study was not placebo controlled and did not establish superiority to tadalafil. The vehicle design, open-label active comparator, single-manufacturer program, and reliance on abstracts and manufacturer material support C with 42 points.
Why this is classified as C (42)
Much of the key efficacy evidence comes from an AUA 2024 conference abstract and manufacturer material, with no full peer-reviewed original efficacy report identified. In FM57 (n=250), MED3000 served as the control vehicle for other drug gels. Therefore, MED3000-specific efficacy versus an inactive placebo cannot be estimated. FM71 randomized 96 participants (48/48) in an open-label, tadalafil active-controlled trial. Its Week 24 within-group IIEF-EF MCID endpoint was met for MED3000, but the study was not placebo controlled and did not establish superiority to tadalafil. The vehicle design, open-label active comparator, single-manufacturer program, and reliance on abstracts and manufacturer material support C with 42 points. Rule ①: (a) improvement only in surrogate biomarkers such as HbA1c, LDL, blood pressure, intraocular pressure, bone density, laboratory values, or imaging has a ceiling of C; (b) a failed primary endpoint with only positive subjective secondary endpoints has a ceiling of C; and (c) small, single-manufacturer, short-term, or conflicting evidence has a ceiling of C. Patient-reported symptoms that are themselves treatment targets, including pain, sleep, bowel function, IRLS, IIEF/SEP, and depression or anxiety scales, are not surrogates. Consistent achievement of clinical-importance thresholds such as MCID in multiple independent randomized trials can support B, and large, consistent, independent evidence can exceptionally support A. If effects do not meet clinical-importance thresholds, the grade remains C regardless of trial count.
Counterpoint. Efficacy was judged separately from safety and regulatory status. Diagnosis and standard treatment choices require clinical discussion.
Rejudgment record. Cross-check applied — Much of the key efficacy evidence comes from an AUA 2024 conference abstract and manufacturer material, with no full peer-reviewed original efficacy report identified. In FM57 (n=250), MED3000 served as the control vehicle for other drug gels. Therefore, MED3000-specific efficacy versus an inactive placebo cannot be estimated. FM71 randomized 96 participants (48/48) in an open-label, tadalafil active-controlled trial. Its Week 24 within-group IIEF-EF MCID endpoint was met for MED3000, but the study was not placebo controlled and did not establish superiority to tadalafil. The vehicle design, open-label active comparator, single-manufacturer program, and reliance on abstracts and manufacturer material support C with 42 points. Rule ①: (a) improvement only in surrogate biomarkers such as HbA1c, LDL, blood pressure, intraocular pressure, bone density, laboratory values, or imaging has a ceiling of C; (b) a failed primary endpoint with only positive subjective secondary endpoints has a ceiling of C; and (c) small, single-manufacturer, short-term, or conflicting evidence has a ceiling of C. Patient-reported symptoms that are themselves treatment targets, including pain, sleep, bowel function, IRLS, IIEF/SEP, and depression or anxiety scales, are not surrogates. Consistent achievement of clinical-importance thresholds such as MCID in multiple independent randomized trials can support B, and large, consistent, independent evidence can exceptionally support A. If effects do not meet clinical-importance thresholds, the grade remains C regardless of trial count.
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Clinically meaningful improvement in IIEF-EF | C | Within-group improvement exceeded MCID, but the gel-specific effect versus placebo or no treatment was not isolated. |
| Improved intercourse success on SEP measures | C | This is a patient-reported treatment target, but evidence depends on a manufacturer program and incomplete publication. |
| Superiority to tadalafil | D | FM71 was an open-label active-controlled trial and did not establish superiority to tadalafil. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| FM57; AUA 2024 conference abstract | Control vehicle for other drug gels in a randomized double-blind parallel trial; conference abstract | FM57 n=250 | Futura Medical | 12-week changes in IIEF-EF and SEP | MED3000 was the control vehicle for other drug gels, so MED3000-specific efficacy versus an inactive placebo cannot be estimated. | Key efficacy evidence |
| FM71; manufacturer material and conference presentation | Randomized open-label tadalafil active-controlled trial; manufacturer material/conference presentation | Randomized n=96 (MED3000 48; tadalafil 48) | Futura Medical | Week 24 within-MED3000 IIEF-EF change exceeding the 4-point MCID | The primary endpoint was met, but there was no placebo control and superiority to tadalafil was not established. | Key efficacy evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] MED3000 x Improved IIEF-EF and intercourse success in men with erectile dysfunction — Evidence Grade C·42. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/med3000-eroxon-erectile-dysfunction-iief-sep/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.